Biotech Values

[DewDiligence]

Re: Radiographic efficacy metric for JAK inhibitors

This passage from the article you posted ought to concern investors in companies who hope to compete with Tofacitinib:

In its briefing documents for the [Tofacitinib] meeting, the FDA raised safety concerns and questions about efficacy, specifically in radiographic outcomes of structural damage progression. Although not required for earlier RA drugs, the agency now wants one radiographic study with a large treatment effect.